IL18 and COVID-19: The inflammasome (NLRP3, associated with IL-18 activation) was reported to be activated during SARS-CoV-2 infection and has been proposed as an indicator of COVID-19 disease severity, predicting the release of pro-inflammatory cytokines that lead to dysregulated immune responses and tissue damage [41].